NYSE: AIM - AIM ImmunoTech Inc.

Lønnsomhet i seks måneder: -50.01%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan AIM ImmunoTech Inc.


Om selskapet AIM ImmunoTech Inc.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).

flere detaljer
It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

IPO date 1996-07-12
ISIN US00901B1052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://aimimmuno.com
Цена ао 0.2969
Prisendring per dag: -3.92% (0.255)
Prisendring per uke: +0.823% (0.243)
Prisendring per måned: -29.6% (0.348)
Prisendring over 3 måneder: -32.02% (0.3604)
Prisendring over seks måneder: -50.01% (0.4901)
Prisendring per år: -57.02% (0.57)
Prisendring over 3 år: -87.63% (1.98)
Prisendring over 5 år: -90.65% (2.62)
Prisendring over 10 år: 0% (0.245)
Prisendring siden begynnelsen av året: -34.84% (0.376)

Undervurdering

Navn Betydning Karakter
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Effektivitet

Navn Betydning Karakter
ROA, % 0 0
ROE, % 0 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA 0 10
Total: 10

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % -61.58 0
Lønnsomhet Ebitda, % 70.45 8
Lønnsomhet EPS, % -92.56 0
Total: 5

ETF Dele, % Lønnsomhet for året, % Utbytte, %
SPDR S&P International Small Cap ETF 0.02113 8.94 3.10348
Dimensional International Small Cap Value ETF 0.00214 7.13 4.55441
SPDR Portfolio Developed World ex-US ETF 0.00183 5.29 3.28401
Avantis Responsible International Equity ETF 0.00127 17.44 3.61591
Dimensional International Small Cap ETF 0.00079 5.69 3.34747
Avantis International Equity ETF 0.0002 6.46 3.80856



Veileder Stillingstittel Betaling Fødselsår
Mr. Thomas K. Equels Esq., J.D., M.S. Executive Vice Chairman, CEO & President 953.19k 1953 (72 år)
Mr. Robert Dickey IV, M.B.A. Chief Financial Officer 64.48k 1956 (69 år)
Mr. Peter W. Rodino III, Esq., J.D. COO, Executive Director of Governmental Relations, General Counsel & Secretary 484.94k 1951 (74 år)
Ann Marie E. Coverly Director of Administration & Human Resources and Deputy Investor Relations Coordinator N/A
Dr. Christopher McAleer Ph.D. Scientific Officer N/A
Dr. Ralph Christopher Cavalli Ph.D. Vice President of QC & Manufacturing 234.79k 1958 (67 år)

Adresse: United States, Ocala. FL, 2117 SW Highway 484 - åpne i Google maps, åpne Yandex-kart
Nettsted: https://aimimmuno.com